FI4168033T3 - CEBP-beta -antagonistin anto ja käyttötavat - Google Patents
CEBP-beta -antagonistin anto ja käyttötavatInfo
- Publication number
- FI4168033T3 FI4168033T3 FIEP21828902.3T FI21828902T FI4168033T3 FI 4168033 T3 FI4168033 T3 FI 4168033T3 FI 21828902 T FI21828902 T FI 21828902T FI 4168033 T3 FI4168033 T3 FI 4168033T3
- Authority
- FI
- Finland
- Prior art keywords
- pharmaceutical composition
- use according
- patient
- intended
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063041991P | 2020-06-21 | 2020-06-21 | |
| US202063041989P | 2020-06-21 | 2020-06-21 | |
| US202063041988P | 2020-06-21 | 2020-06-21 | |
| US202063041990P | 2020-06-21 | 2020-06-21 | |
| US202063041986P | 2020-06-21 | 2020-06-21 | |
| US202163172560P | 2021-04-08 | 2021-04-08 | |
| PCT/US2021/038264 WO2021262604A2 (en) | 2020-06-21 | 2021-06-21 | Administration of cebp-beta antagonist and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4168033T3 true FI4168033T3 (fi) | 2026-04-07 |
Family
ID=79281738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21828902.3T FI4168033T3 (fi) | 2020-06-21 | 2021-06-21 | CEBP-beta -antagonistin anto ja käyttötavat |
Country Status (17)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119997967A (zh) * | 2022-10-07 | 2025-05-13 | 智慧疗法有限公司 | C/EBP-β拮抗剂和免疫调节剂的使用 |
| WO2024216238A2 (en) * | 2023-04-13 | 2024-10-17 | Sapience Therapeutics, Inc. | Use of beta-catenin antagonist and immunomodulator |
| EP4694911A2 (en) * | 2023-04-13 | 2026-02-18 | Sapience Therapeutics, Inc. | Administration of a beta-catenin antagonist and methods of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105228642A (zh) * | 2013-02-22 | 2016-01-06 | 纽约市哥伦比亚大学理事会 | 通过抑制转录因子atf5来抑制肿瘤细胞的组合物和方法 |
| CA2983030A1 (en) * | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia |
| WO2018152446A2 (en) | 2017-02-20 | 2018-08-23 | Sapience Therapeutics, Inc. | Cell-penetrating atf5 polypeptides and uses thereof |
| PT3737399T (pt) | 2018-01-03 | 2023-09-04 | Sapience Therapeutics Inc | Variantes do péptido atf5 e as respetivas utilizações |
| WO2020033555A2 (en) * | 2018-08-08 | 2020-02-13 | The Trustees Of Columbia University In The City Of New York | Dominant negative cebpb and cebpd proteins and methods of use for decreasing viability of neoplastic cells |
-
2021
- 2021-06-21 AU AU2021297172A patent/AU2021297172B2/en active Active
- 2021-06-21 WO PCT/US2021/038264 patent/WO2021262604A2/en not_active Ceased
- 2021-06-21 CA CA3180559A patent/CA3180559A1/en active Pending
- 2021-06-21 DK DK21828902.3T patent/DK4168033T3/da active
- 2021-06-21 BR BR112022025880A patent/BR112022025880A2/pt unknown
- 2021-06-21 KR KR1020227044587A patent/KR20230027054A/ko active Pending
- 2021-06-21 FI FIEP21828902.3T patent/FI4168033T3/fi active
- 2021-06-21 EP EP21828902.3A patent/EP4168033B1/en active Active
- 2021-06-21 PT PT218289023T patent/PT4168033T/pt unknown
- 2021-06-21 ES ES21828902T patent/ES3066151T3/es active Active
- 2021-06-21 MX MX2022016478A patent/MX2022016478A/es unknown
- 2021-06-21 IL IL299104A patent/IL299104A/en unknown
- 2021-06-21 NZ NZ795026A patent/NZ795026A/en unknown
- 2021-06-21 JP JP2022579019A patent/JP7880618B2/ja active Active
- 2021-06-21 US US18/011,171 patent/US20230218717A1/en active Pending
- 2021-06-21 CN CN202180044276.8A patent/CN115768458A/zh active Pending
-
2022
- 2022-12-05 ZA ZA2022/13167A patent/ZA202213167B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES3066151T3 (en) | 2026-05-11 |
| EP4168033A4 (en) | 2024-06-19 |
| AU2021297172A1 (en) | 2023-01-19 |
| KR20230027054A (ko) | 2023-02-27 |
| EP4168033B1 (en) | 2026-02-25 |
| US20230218717A1 (en) | 2023-07-13 |
| IL299104A (en) | 2023-02-01 |
| PT4168033T (pt) | 2026-03-24 |
| BR112022025880A2 (pt) | 2023-01-10 |
| JP7880618B2 (ja) | 2026-06-26 |
| AU2021297172B2 (en) | 2025-01-30 |
| DK4168033T3 (da) | 2026-05-11 |
| MX2022016478A (es) | 2023-02-01 |
| ZA202213167B (en) | 2026-03-25 |
| CA3180559A1 (en) | 2021-12-30 |
| EP4168033A2 (en) | 2023-04-26 |
| NZ795026A (en) | 2026-03-27 |
| JP2023531683A (ja) | 2023-07-25 |
| WO2021262604A3 (en) | 2022-02-17 |
| WO2021262604A2 (en) | 2021-12-30 |
| CN115768458A (zh) | 2023-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250213515A1 (en) | Methods for the treatment of glioblastoma multiforme | |
| ES2836424T3 (es) | Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración | |
| CN101669941B (zh) | 一种联合用药治疗恶性肿瘤的方法以及抗恶性肿瘤的药物 | |
| Yan et al. | Engineering immunogenic cell death with nanosized drug delivery systems improving cancer immunotherapy | |
| KR101628448B1 (ko) | 암 치료에 사용하기 위한 베무라페닙 및 인터페론을 포함하는 병용 요법 | |
| JP2006290863A (ja) | 胃腸障害の治療 | |
| AU2017272098B2 (en) | Improved therapeutic index of anti-immune checkpoint inhibitors using combination therapy comprising a PHY906 extract, a Scutellaria baicalensis GeorgI (S) extract or a compound from such extracts | |
| KR20130118981A (ko) | 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물 | |
| JP2022551672A (ja) | 乳癌治療法 | |
| JP2020536903A5 (cg-RX-API-DMAC7.html) | ||
| Yang et al. | Pharmacological management of cancer pain: Advances in treatment strategies and drug delivery systems | |
| CN104321074B (zh) | 生长抑素类似物与11β‑羟化酶抑制剂的组合 | |
| CN107137407B (zh) | 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途 | |
| US20260041676A1 (en) | Combination Therapy | |
| Bravo | Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease | |
| Aschhoff | Retrospective study of Ukrain treatment in 203 patients with advanced-stage tumors | |
| JP2000507207A (ja) | 複合注射剤 | |
| TW201244732A (en) | Ezatiostat for treating multiple myeloma | |
| RU2013149175A (ru) | Лекарственное средство, содержащее лектины омелы, для лечения злокачественной меланомы | |
| Rosenberg et al. | Oral biologics: the new wave for treating psoriasis | |
| Caulin et al. | 456 100% complete response to PEEL-224 in combination with PD-1 blockade in a syngeneic mouse model of colon cancer | |
| RU2271831C1 (ru) | Способ лечения онкологических заболеваний | |
| RU2025107889A (ru) | Комбинация талазопариба и энзалутамида при лечении метастатического кастрационно-резистентного рака предстательной железы | |
| Baurain et al. | A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced sarcoma | |
| CN107375299A (zh) | 一种积雪草酸的新用途及含积雪草酸的抗肿瘤药物组合 |